SKLB-163
SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI) . SKLB-163 inhibits highly expressed RhoGDI tumor cell proliferation and migration, and increases radiosensitivity of tumor cells. SKLB-163 induces cancer cell Apoptosis[1][2].
Product Specifications
CAS Number
1255099-06-9
UNSPSC
12352005
Target
Apoptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sklb-163.html
Solubility
10 mM in DMSO
Smiles
O=C(CSC1=NC2=CC=C(C=C2S1)NC(CCl)=O)NCC3=CC=CC=C3
Molecular Formula
C18H16ClN3O2S2
Molecular Weight
405.92
References & Citations
[1]He J, et al. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway. Radiother Oncol. 2018 Oct;129 (1) :30-37.|[2]Peng X, et al. SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis. 2014 Mar 27;5 (3) :e1143.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040896-100 1x 100 µL
PDCD1 / PD1 / CD279 (Programmed Cell Death 1) (NAT105), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
LY427332 100 µg
NELF (NSMF) (NM_001130970) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC682249-100 1x 100 µL
Transthyretin (Prealbumin) (CPTC-TTR-1), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details